nach oben

Endocrine

Erschienen in:

11.08.2023 | Meta- Analysis

Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Muhammad Omar Larik, Ayesha Ahmed, Laiba Khan, Muhammad Ashhal Iftekhar

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Polycystic ovarian syndrome (PCOS) is the heightened ovarian dysfunction associated with excessive androgen production, manifesting with hirsutism, abnormal menstrual cycle, and polycystic ovaries. In this systematic review and meta-analysis, the effect of resveratrol on laboratory parameters of PCOS women will be assessed.

Methods

An electronic search via PubMed, Cochrane Library, and Scopus was performed up to February 2023 for randomized controlled trials conforming to our pre-specified outcomes. A random-effects model was utilized, with cohorts compared using mean differences.

Results

Three randomized controlled trials (RCTs) were included, reporting 84 patients receiving resveratrol, and 85 patients receiving placebo. It was observed that resveratrol significantly improved prolactin levels (P = 0.02), acne scores (P = 0.008), and total cholesterol (P = 0.02). However, there were no significant improvements observed with respect to total testosterone, follicle stimulating hormone (FSH), lutenizing hormone (LH), body mass index (BMI), hirsutism scores, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL).

Conclusion

As per the results of our analysis, resveratrol demonstrates mild therapeutic potential for the sufferers of PCOS, and cannot replace the current established treatment guidelines. However, further comprehensive RCTs are required in order to assess the efficacy in long-term dosing and the safety profile of the use of resveratrol.

Nur mit Berechtigung zugänglich

R. Azziz, E. Carmina, D. Dewailly et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91, 456–488 (2009). https://doi.org/10.1016/j.fertnstert.2008.06.035CrossRefPubMed

W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25, 544–551 (2010). https://doi.org/10.1093/humrep/dep399CrossRefPubMed

E.M. Okoroh, W.C. Hooper, H.K. Atrash, H.R. Yusuf, S.L. Boulet, Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008. Am J Obstet Gynecol 207, 299.e1–7 (2012). https://doi.org/10.1016/j.ajog.2012.07.023CrossRefPubMed

D. Lizneva, L. Suturina, W. Walker, S. Brakta, L. Gavrilova-Jordan, R. Azziz, Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106, 6–15 (2016). https://doi.org/10.1016/j.fertnstert.2016.05.003CrossRefPubMed

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, 41–47 (2004). https://doi.org/10.1093/humrep/deh098CrossRef

S. Abdollahi, A. Salehi-Abargouei, O. Toupchian et al. The effect of resveratrol supplementation on cardio-metabolic risk factors in patients with type 2 diabetes: a randomized, double-blind controlled trial. Phytother Res 33, 3153–3162 (2019). https://doi.org/10.1002/ptr.6487CrossRefPubMed

A.Y. Berman, R.A. Motechin, M.Y. Wiesenfeld, M.K. Holz, The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis. Oncol. 1, 35 (2017). https://doi.org/10.1038/s41698-017-0038-6CrossRef

C. Buhrmann, P. Shayan, B. Popper, A. Goel, M. Shakibaei, Sirt1 is required for resveratrol-mediated chemopreventive effects in colorectal cancer cells. Nutrients. 8, 145 (2016). https://doi.org/10.3390/nu8030145CrossRefPubMedPubMedCentral

K. Farhadi, F. Esmaeilzadeh, M. Hatami, M. Forough, R. Molaie, Determination of phenolic compounds content and antioxidant activity in skin, pulp, seed, cane and leaf of five native grape cultivars in West Azerbaijan province, Iran. Food Chem 199, 847–855 (2016). https://doi.org/10.1016/j.foodchem.2015.12.083CrossRefPubMed

10.

S. Shojaei-Zarghani, M. Rafraf, Resveratrol and markers of polycystic ovary syndrome: a systematic review of animal and clinical studies. Reprod Sci 29, 2477–2487 (2022). https://doi.org/10.1007/s43032-021-00653-9CrossRefPubMed

11.

S. Furat Rencber, S. Kurnaz Ozbek, C. Eraldemır et al. Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res 11, 55 (2018). https://doi.org/10.1186/s13048-018-0427-7CrossRefPubMedPubMedCentral

12.

A. Mansour, M. Samadi, M. Sanginabadi et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin Nutr 40, 4106–4112 (2021). https://doi.org/10.1016/j.clnu.2021.02.004CrossRefPubMed

13.

B. Yuan, S. Luo, L. Feng, J. Wang, J. Mao, B. Luo, Resveratrol regulates the inflammation and oxidative stress of granulosa cells in PCOS via targeting TLR2. J Bioenerg Biomembr 54, 191–201 (2022). https://doi.org/10.1007/s10863-022-09942-7CrossRefPubMed

14.

M.J. Page, J.E. McKenzie, P.M. Bossuyt et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

15.

J.P. Higgins, D.G. Altman, P.C. Gøtzsche et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343, d5928 (2011). https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

16.

J.P. Higgins, S.G. Thompson, J. J. Deeks et al. Measuring inconsistency in meta-analyses. BMJ. 327, 557–560 (2003). https://doi.org/10.1136/bmj.327.7414.557

17.

M. Bahramrezaie, F. Amidi, A. Aleyasin et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet. 36, 1701–1712 (2019). https://doi.org/10.1007/s10815-019-01461-6CrossRefPubMedPubMedCentral

18.

B. Banaszewska, J. Wrotyńska-Barczyńska, R.Z. Spaczynski, L. Pawelczyk, A.J. Duleba, Effects of resveratrol on polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 101, 4322–4328 (2016). https://doi.org/10.1210/jc.2016-1858CrossRefPubMed

19.

C.M. Burt Solorzano, J.P. Beller, M.Y. Abshire, J.S. Collins, C.R. McCartney, J.C. Marshall, Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 77, 332–337 (2012). https://doi.org/10.1016/j.steroids.2011.12.007CrossRefPubMed

20.

S.K. Blank, C.R. McCartney, S. Chhabra, K.D. Helm, C.A. Eagleson, R.J. Chang, J.C. Marshall, Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. J Clin Endocrinol Metab. 94, 2360–2366 (2009). https://doi.org/10.1210/jc.2008-2606CrossRefPubMedPubMedCentral

21.

V. De Leo, M.C. Musacchio, V. Cappelli, M.G. Massaro, G. Morgante, F. Petraglia, Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 14, 38 (2016). https://doi.org/10.1186/s12958-016-0173-xCrossRefPubMedPubMedCentral

22.

D. Dewailly, G. Robin, M. Peigne, C. Decanter, P. Pigny, S. Catteau-Jonard, Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 22, 709–724 (2016). https://doi.org/10.1093/humupd/dmw027CrossRefPubMed

23.

F. Naftolin, G. Tolis, Neuroendocrine regulation of the menstrual cycle. Clin Obstet Gynecol 21, 17–29 (1978). https://doi.org/10.1097/00003081-197803000-00003CrossRefPubMed

24.

W. Chao, Z. Xuexin, S. Jun, C. Ming, J. Hua, G. Li, C. Tan, W. Xu, Effects of resveratrol on cell growth and prolactin synthesis in GH3 cells. Exp Ther Med. 7, 923–928 (2014). https://doi.org/10.3892/etm.2014.1544CrossRefPubMedPubMedCentral

25.

C. Wang, Z.Q. Hu, M. Chu, Z. Wang, W.G. Zhang, L.Z. Wang, C.G. Li, J.S. Wang, Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors. Clin Neurol Neurosurg. 114, 241–248 (2012). https://doi.org/10.1016/j.clineuro.2011.10.035CrossRefPubMed

26.

Q. Liu, Y.J. Xie, L.H. Qu, M.X. Zhang, Z.C. Mo, Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol 58, 447–453 (2019). https://doi.org/10.1016/j.tjog.2019.05.003CrossRefPubMed

27.

A. Liang, L. Huang, H. Liu et al. Resveratrol improves follicular development of pcos rats by regulating the glycolytic pathway. Mol Nutr Food Res. 65, e2100457 (2021). https://doi.org/10.1002/mnfr.202100457CrossRefPubMed

28.

E. Diamanti-Kandarakis, A.G. Papavassiliou, S.A. Kandarakis, G.P. Chrousos, Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 18, 280–285 (2007). https://doi.org/10.1016/j.tem.2007.07.004CrossRefPubMed

29.

D. Macut, J. Bjekić-Macut, A. Savić-Radojević, Dyslipidemia and oxidative stress in PCOS. Front Horm Res. 40, 51–63 (2013). https://doi.org/10.1159/000341683CrossRefPubMed

30.

R.A. Wild, Dyslipidemia in PCOS. Steroids. 77, 295–299 (2012). https://doi.org/10.1016/j.steroids.2011.12.002CrossRefPubMed

31.

D. Thiboutot, K. Gilliland, J. Light, D. Lookingbill, Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 135, 1041–1045 (1999). https://doi.org/10.1001/archderm.135.9.1041CrossRefPubMed

32.

S.B. Reingold, R.L. Rosenfield, The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 123, 209–212 (1987)CrossRefPubMed

33.

F. Ramezani Tehrani, S. Behboudi-Gandevani, R. Bidhendi Yarandi, M. Saei Ghare Naz, E. Carmina, Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 37, 392–405 (2021). https://doi.org/10.1080/09513590.2020.1859474CrossRefPubMed

34.

M. Lebbe, T.K. Woodruff, Involvement of androgens in ovarian health and disease. Mol Hum Reprod. 19, 828–837 (2013). https://doi.org/10.1093/molehr/gat065CrossRefPubMedPubMedCentral

35.

A. Ochiai, K. Kuroda, R. Ozaki et al. Resveratrol inhibits decidualization by accelerating downregulation of the CRABP2-RAR pathway in differentiating human endometrial stromal cells. Cell Death Dis. 10, 276 (2019). https://doi.org/10.1038/s41419-019-1511-7CrossRefPubMedPubMedCentral

36.

S.K. Manna, A. Mukhopadhyay, B.B. Aggarwal, Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164, 6509–6519 (2000). https://doi.org/10.4049/jimmunol.164.12.6509CrossRefPubMed

37.

B.B. Aggarwal, S. Shishodia, Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann N Y Acad Sci 1030, 434–441 (2004). https://doi.org/10.1196/annals.1329.054CrossRefPubMed

38.

S. Brenjian, A. Moini, N. Yamini, L. Kashani, M. Faridmojtahedi, M. Bahramrezaie, M. Khodarahmian, F. Amidi, Resveratrol treatment in patients with polycystic ovary syndrome decreased pro-inflammatory and endoplasmic reticulum stress markers. Am J Reprod Immunol 83, e13186 (2020). https://doi.org/10.1111/aji.13186CrossRefPubMed

39.

J.C. Nwachukwu, S. Srinivasan, N.E. Bruno et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. Elife. 3, e02057 (2014). https://doi.org/10.7554/eLife.02057CrossRefPubMedPubMedCentral

40.

S. Hassan, M. Shah, M.O. Malik, E. Ehtesham, S.H. Habib, B. Rauf, Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial. Endocrine. 79, 208–220 (2023). https://doi.org/10.1007/s12020-022-03198-2CrossRefPubMed

41.

S. Furat Rencber, S. Kurnaz Ozbek, C. Eraldemır, Z. Sezer, T. Kum, S. Ceylan, E. Guzel, Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res. 11, 55 (2018). https://doi.org/10.1186/s13048-018-0427-7CrossRefPubMedPubMedCentral

42.

U. Schube, M. Nowicki, P. Jogschies, V. Blumenauer, I. Bechmann, H. Serke, Resveratrol and desferoxamine protect human OxLDL-treated granulosa cell subtypes from degeneration. J Clin Endocrinol Metab. 99, 229–239 (2014). https://doi.org/10.1210/jc.2013-2692CrossRefPubMed

43.

B. Salehi, A.P. Mishra, M. Nigam et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 6, 91 (2018). https://doi.org/10.3390/biomedicines6030091CrossRefPubMedPubMedCentral

Titel: Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials
verfasst von: Muhammad Omar Larik
Ayesha Ahmed
Laiba Khan
Muhammad Ashhal Iftekhar
Publikationsdatum: 11.08.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03479-4

SARS-CoV-2 spread to endocrine organs is associated with obesity: an autopsy study of COVID-19 cases

Open Access
Original Article

Diabetes and ovarian cancer: risk factors, molecular mechanisms and impact on prognosis

Review

Screening for primary aldosteronism on and off interfering medications

Original Article

Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma

Original Article

A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease

Brief report

Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

13.01.2025
Kolektomie
Nachrichten

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

12.01.2025
Koronare Herzerkrankung
Nachrichten

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Inhalative Steroide bei COPD nicht kardioprotektiv

10.01.2025
COPD
Nachrichten

Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials